• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review.双膦酸盐类药物所致乳腺癌患者颌骨坏死：一项系统评价
J Oral Maxillofac Pathol. 2012 May;16(2):210-4. doi: 10.4103/0973-029X.98893.
2
Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges.定义双膦酸盐相关性颌骨骨坏死的流行病学：既往研究与当前挑战。
Osteoporos Int. 2013 Jan;24(1):237-44. doi: 10.1007/s00198-012-2042-6. Epub 2012 Jun 16.
3
Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw.双膦酸盐相关颌骨坏死的癌症患者的资源利用情况。
Oral Dis. 2014 Jan;20(1):94-9. doi: 10.1111/odi.12080. Epub 2013 Feb 19.
4
Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.全景片、计算机断层扫描或磁共振成像。在双膦酸盐相关性颌骨骨坏死中，应优先选择哪种影像学技术？一项前瞻性临床研究。
Clin Oral Investig. 2010 Jun;14(3):311-7. doi: 10.1007/s00784-009-0293-1. Epub 2009 Jun 10.
5
Bisphosphonates and osteonecrosis of the jaw--current thoughts.双膦酸盐与颌骨坏死——当前观点
Dent Update. 2009 Sep;36(7):415-9. doi: 10.12968/denu.2009.36.7.415.
6
Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.双膦酸盐可引起小鼠类似下颌骨坏死的疾病。
Am J Pathol. 2010 Jul;177(1):280-90. doi: 10.2353/ajpath.2010.090592. Epub 2010 May 14.
7
Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient.口服双膦酸盐治疗与颌骨坏死：该告知相关患者什么。
Int J Prosthodont. 2007 Mar-Apr;20(2):115-22.
8
Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?窦道——双膦酸盐相关颌骨坏死的早期迹象？
J Oral Maxillofac Surg. 2009 Mar;67(3):593-601. doi: 10.1016/j.joms.2008.09.031.
9
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.关于口服双膦酸盐治疗的骨质疏松症患者颌骨坏死的文献综述：患病率、危险因素及临床特征
Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008.
10
Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.乳腺癌患者中双膦酸盐相关颌骨坏死的发生率。
Cancer. 2009 Apr 15;115(8):1631-7. doi: 10.1002/cncr.24119.

引用本文的文献

1
Bone Health Considerations in Breast Cancer.乳腺癌的骨骼健康考虑因素。
Semin Oncol Nurs. 2022 Apr;38(2):151273. doi: 10.1016/j.soncn.2022.151273. Epub 2022 Apr 25.
2
Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.香叶基香叶醇加成影响双膦酸盐的效力——体外比较有望为双膦酸盐相关性颌骨坏死和口腔伤口愈合提供一种治疗方法。
Oral Maxillofac Surg. 2022 Jun;26(2):321-332. doi: 10.1007/s10006-021-00982-8. Epub 2021 Aug 15.
3
Association of common comorbidities with osteonecrosis: a nationwide population-based case-control study in Denmark.常见合并症与骨坏死的关联：丹麦一项基于全国人口的病例对照研究。
BMJ Open. 2018 Feb 8;8(2):e020680. doi: 10.1136/bmjopen-2017-020680.
4
Prevalence of osteonecrosis of the jaw and oral characteristics of oncologic patients treated with bisphosphonates at the General Hospital of Mexico.墨西哥总医院接受双膦酸盐治疗的肿瘤患者颌骨骨坏死患病率及口腔特征
J Korean Assoc Oral Maxillofac Surg. 2016 Dec;42(6):365-369. doi: 10.5125/jkaoms.2016.42.6.365. Epub 2016 Dec 27.
5
Risk Assessment of BRONJ in Oncologic Patients Treated with Bisphosphonates: Follow-Up to 18 Months.接受双膦酸盐治疗的肿瘤患者发生颌骨坏死的风险评估：长达18个月的随访
Int J Dent. 2014;2014:475859. doi: 10.1155/2014/475859. Epub 2014 Sep 1.
6
An NMR metabolomic study on the effect of alendronate in ovariectomized mice.一项关于阿仑膦酸盐对去卵巢小鼠影响的核磁共振代谢组学研究。
PLoS One. 2014 Sep 3;9(9):e106559. doi: 10.1371/journal.pone.0106559. eCollection 2014.
7
Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis.服用双膦酸盐预防骨质疏松症患者的骨坏死风险：一项系统评价和荟萃分析。
Osteoporos Int. 2014 Mar;25(3):1131-9. doi: 10.1007/s00198-013-2575-3. Epub 2013 Dec 17.
8
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.接受地诺单抗治疗的癌症患者发生颌骨坏死的风险：七项随机对照试验的荟萃分析
Int J Clin Oncol. 2014 Apr;19(2):403-10. doi: 10.1007/s10147-013-0561-6. Epub 2013 Apr 20.
9
Histology of the Oral Mucosa in Patients With BRONJ at III Stage: A Microscopic Study Proves the Unsuitability of Local Mucosal Flaps.III期BRONJ患者口腔黏膜的组织学：一项微观研究证明局部黏膜瓣不适用。
J Clin Med Res. 2013 Feb;5(1):22-5. doi: 10.4021/jocmr1253e. Epub 2013 Jan 11.

本文引用的文献

1
Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.双膦酸盐相关骨坏死：遗传和后天危险因素
Oral Dis. 2009 Sep;15(6):382-7. doi: 10.1111/j.1601-0825.2009.01568.x. Epub 2009 Apr 22.
2
Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.乳腺癌患者中双膦酸盐相关颌骨坏死的发生率。
Cancer. 2009 Apr 15;115(8):1631-7. doi: 10.1002/cncr.24119.
3
Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.双膦酸盐类药物所致颌骨坏死（ONJ）：乳腺癌和妇科恶性肿瘤患者中的发病率及危险因素
Gynecol Oncol. 2009 Mar;112(3):605-9. doi: 10.1016/j.ygyno.2008.11.029. Epub 2009 Jan 12.
4
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.双膦酸盐相关颌骨坏死与多发性骨髓瘤中细胞色素P450 CYP2C8的多态性相关：一项全基因组单核苷酸多态性分析
Blood. 2008 Oct 1;112(7):2709-12. doi: 10.1182/blood-2008-04-147884. Epub 2008 Jul 1.
5
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.接受静脉注射双膦酸盐治疗的癌症患者颌骨坏死的发生率及相关危险因素。
J Bone Miner Res. 2008 Jun;23(6):826-36. doi: 10.1359/jbmr.080205.
6
Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study.双膦酸盐治疗骨转移患者颌骨坏死的回顾性研究。
Oncologist. 2008 Mar;13(3):330-6. doi: 10.1634/theoncologist.2007-0159.
7
Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis.双膦酸盐类药物的最新进展以及双膦酸盐类药物所致颌骨坏死的潜在病理生物学机制
Oral Dis. 2008 Apr;14(3):277-85. doi: 10.1111/j.1601-0825.2007.01381.x.
8
Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.双膦酸盐类药物所致颌骨坏死：80例多发性骨髓瘤及其他恶性肿瘤患者的前瞻性研究
Oral Oncol. 2008 Sep;44(9):857-69. doi: 10.1016/j.oraloncology.2007.11.012. Epub 2008 Feb 20.
9
Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.接受静脉注射双膦酸盐治疗的多发性骨髓瘤、乳腺癌或前列腺癌患者颌骨坏死的发生率。
J Oral Maxillofac Surg. 2007 Jul;65(7):1328-31. doi: 10.1016/j.joms.2007.03.006.
10
Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.接受唑来膦酸治疗骨转移患者的肾毒性及颌骨骨坏死评估
Ann Oncol. 2007 Mar;18(3):556-60. doi: 10.1093/annonc/mdl408. Epub 2006 Nov 2.

双膦酸盐类药物所致乳腺癌患者颌骨坏死：一项系统评价

Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review.

作者信息

Varun Br, Sivakumar Tt, Nair Bindu J, Joseph Anna P

机构信息

Department of Oral and Maxillofacial Pathology, PMS Institute of Dental Science and Research, Trivandrum, Kerala, India.

出版信息

J Oral Maxillofac Pathol. 2012 May;16(2):210-4. doi: 10.4103/0973-029X.98893.

DOI:10.4103/0973-029X.98893
PMID:22923892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3424936/
Abstract

BACKGROUND

Bisphosphonate therapy is widely used for the treatment of bone metastasis in breast cancer patients.

AIM

The aim of this study is to estimate the overall prevalence of bisphosphonate induced osteonecrosis of jaw (BONJ) in breast cancer patients with bone metastasis.

MATERIALS AND METHODS

A literature review was conducted to search and evaluate all the articles that contained original data on the prevalence of BONJ in breast cancer patients from the year 2003-2009. Pubmed search terms used were bisphosphonate, osteonecrosis, breast cancer and jaw. Eleven publications that fulfilled the inclusion criteria were chosen for the study. Case reports and reviews were excluded from the analysis based on assessing the title and abstract.

RESULTS

Of the 2490 breast cancer patients, 69 developed BONJ with the overall prevalence rate of 2.8%. All the patients with BONJ had received zoledronate or pamidronate, either alone or in combinations.

CONCLUSION

BONJ is a significant complication occurring in 2.8% of the breast cancer patients receiving bisphosphonates for metastatic bone disease. It is very important to identify the trigger factors associated with BONJ and also to establish guidelines for the prevention and effective treatment of this condition.

摘要

背景

双膦酸盐疗法广泛用于治疗乳腺癌患者的骨转移。

目的

本研究旨在评估双膦酸盐诱导的颌骨坏死（BONJ）在骨转移乳腺癌患者中的总体患病率。

材料与方法

进行文献综述，以检索和评估2003年至2009年间所有包含乳腺癌患者BONJ患病率原始数据的文章。在Pubmed中使用的检索词为双膦酸盐、骨坏死、乳腺癌和颌骨。选择了11篇符合纳入标准的出版物进行研究。根据标题和摘要评估，将病例报告和综述排除在分析之外。

结果

在2490例乳腺癌患者中，69例发生BONJ，总体患病率为2.8%。所有发生BONJ的患者均单独或联合接受过唑来膦酸或帕米膦酸治疗。

结论

BONJ是接受双膦酸盐治疗转移性骨病的乳腺癌患者中出现的一种严重并发症，发生率为2.8%。识别与BONJ相关的触发因素以及制定该疾病的预防和有效治疗指南非常重要。